Clindamycin Impurity B is a known impurity and degradation product of the antibiotic clindamycin. It is chemically identified as clindamycin sulfoxide, formed through the oxidation of the sulfur atom in the parent compound's thioglycoside moiety. This structural modification significantly alters its biological activity. As a specified impurity, Clindamycin Impurity B is critical in the pharmaceutical quality control process. It is used as a reference standard (impurity standard) in analytical methods, such as HPLC, to monitor and control the purity of clindamycin drug substances and finished pharmaceutical products. Its presence and concentration are regulated to ensure the safety, efficacy, and stability of clindamycin-based medications, which are primarily used to treat serious anaerobic bacterial infections. The compound is essential for compliance with pharmacopoeial standards (e.g., USP, EP) and regulatory requirements (e.g., ICH guidelines) during drug development and manufacturing. Its characterization and controlled levels are vital for assessing the stability profile and shelf-life of clindamycin formulations.